Psyence Biomedical (NASDAQ:PBM) Stock Falls 11.3% – Time to Sell?

Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report)’s share price dropped 11.3% during trading on Tuesday. The company traded as low as $2.51 and last traded at $2.51. 65,336 shares were traded during trading, an increase of 22% from the average daily volume of 53,460 shares. The stock had previously closed at $2.83.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Psyence Biomedical in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Psyence Biomedical to a “hold” rating in a report on Saturday, October 3rd. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Check Out Our Latest Report on PBM

Psyence Biomedical Stock Down 11.3%

The firm’s 50 day moving average is $4.50 and its 200-day moving average is $3.88. The firm has a market cap of $5.75 million, a PE ratio of 0.10 and a beta of 1.72.

About Psyence Biomedical

(Get Free Report)

Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company developing nature-derived psychedelic treatments for mental health and palliative care. Its research focuses on psilocybin, a psychedelic compound, for potential use in supervised therapeutic settings. The company’s lead candidate, PEX010, is a naturally derived psilocybin product being studied for adjustment disorder in people receiving palliative care. Psyence Biomedical’s work centers on clinical development and evaluating the safety and potential therapeutic effects of this treatment.

Further Reading

Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.